Expert Panel Review and Practical Guidance on Biomarker Testing with Engineered Immune Effector Cells

Area of Science:

• Immunotherapy
• Hematologic Malignancies
• Biomarker Discovery

Background:

• Chimeric antigen receptor (CAR) T-cell therapy has transformed hematologic malignancy treatment.
• Inconsistent biomarker assays hinder comparability, translational insights, and evidence-based decisions.
• Standardized frameworks are vital as CAR T-cell therapy expands to new platforms and indications.

Purpose of the Study:

• To establish harmonized biomarker testing practices for CAR T-cell therapy.
• To provide evidence-based recommendations on biomarker selection, timing, and application.
• To inform toxicity management, guide treatment decisions, and support future research.

Main Methods:

• A multidisciplinary expert panel reviewed current literature and clinical practices.
• Consensus was reached on recommendations for laboratory assessments, cytokine profiling, and CAR T-cell monitoring.
• Biomarkers were tiered into 'must-have,' 'can-have,' and 'nice-to-have' categories.

Main Results:

• Comprehensive baseline laboratory testing is recommended before lymphodepletion.
• Serial measurements of inflammatory markers and cytokines are advised during toxicity phases.
• CAR T-cell monitoring should be performed at defined intervals; cytokines and CAR-T kinetics may predict toxicity or non-response.

Conclusions:

• Standardized biomarker testing is essential for improving patient outcomes and advancing CAR T-cell therapy.
• These recommendations offer a framework for clinical implementation and future research.
• Harmonized practices bridge routine care with next-generation biomarker-driven strategies.